CAR T-cell immunotherapy of B-cell malignancy: the story so far. (May 2020)

• Record Type: Journal Article
• Authors: Halim, Leena; Maher, John
• Is Part Of: Therapeutic advances in vaccines and immunotherapy. Volume 8(2020)
• Publication Date: 2020-05
• Subjects: B-cell -- CD19 -- chimeric antigen receptor -- clinical trial -- leukaemia -- lymphoma; Vaccines -- Biotechnology -- Periodicals; Immunotherapy -- Periodicals; 615.372
• DOI: 10.1177/2515135520927164
• Languages: English
• ISSNs: 2515-1355

Abstract

Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell products by the United States Food and Drug Administration and European Medicines Agency. However, several issues associated with CAR T-cell treatment remain unresolved, such as the management of severe toxicities and the frequent occurrence of both antigen-positive and antigen-negative relapse. Nonetheless, pre-clinical research is advancing at an unprecedented pace to develop innovative solutions to address these issues. Herein, we summarise recent clinical developments and outcomes of CD19-targeted CAR T-cell immunotherapy and discuss emerging strategies that may further improve the success, safety and broadened applicability of this approach.